Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-21

Clinical Trial Update: 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pentamidine in patients with relapsed or refractory melanoma was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pentamidine (pentamidine)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Melanoma (Skin) | Phase 2 | Status: TERMINATED | Results posted: 2016-10-21